HEALTH● LOWSep 26 · Sep 26, 2026, 1:54 PM
Mirum and Incyte gain approval of zilurgisertib for rare bone disorder
Seeking Alpha Tech · global
Two companies, Mirum and Incyte, have received approval for a drug named zilurgisertib, intended to treat a rare bone disorder. This approval marks a significant development in the treatment options available for patients with this condition.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH1h agoKenya’s Ebola cases test preparedness beyond NairobiAl Jazeera [en]HEALTH2h agoEven after explosive diarrhea outbreak Trump’s FDA looks to ease food requirementsThe Independent WorldHEALTH4h agoPope Leo recovers after lung surgeryNBC NewsHEALTH5h agoThe health of Leo XIV: the Pope advances in his recovery, but uncertainty remains about his visit to South AmericaClarín